Crizotinib (PF-02341066)

For research use only. Not for use in humans.

Pfizer辉瑞授权目录号：S1068

Crizotinib (PF-02341066) Chemical Structure

Molecular Weight(MW): 450.34

Crizotinib (PF-02341066) 克唑替尼是一种有效的c-Met和ALK抑制剂，在细胞试验中IC50分别为11 nM 和 24 nM。它同时也是有效的ROS1抑制剂，其Ki值小于0.025 nM。Crizotinib可在多种肺癌细胞系中通过抑制STAT3通路来诱导自噬。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1812.55	现货
5mg	RMB 900.49	现货
10mg	RMB 1372.81	现货
50mg	RMB 4681.47	现货
大包装	有超大折扣

大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Crizotinib (PF-02341066)发表文献255篇：

Cancer Cell, 2020, 13;37(1):104-122e12

PubMed: 31935369 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nat Med, 2018, 24(7):968-977

PubMed: 29808010 ( click the link to review the publication )

Cell, 2018, 174(4):856-869

PubMed: 30096312 ( click the link to review the publication )

Cancer Cell, 2018, 34(6):922-938

PubMed: 30537514 ( click the link to review the publication )

Nat Chem Biol, 2017, 13(6):681-690

PubMed: 28437395 ( click the link to review the publication )

Nature, 2016, 30;534(7609):647-51.

PubMed: 27338794 ( click the link to review the publication )

J Clin Oncol, 2016, 34(8):794-802

PubMed: 26215952 ( click the link to review the publication )

Nat Med, 2015, 21(9):1038-47

PubMed: 26301689 ( click the link to review the publication )

Cancer Discov, 2015, 5(9):960-971

PubMed: 26036643 ( click the link to review the publication )

Cancer Discov, 2015, 10.1158/2159-8290.CD-15-0913

PubMed: 26566875 ( click the link to review the publication )

Cancer Cell, 2015, 27(3):397-408

PubMed: 25759024 ( click the link to review the publication )

Cancer Cell, 2015, 27(4):533-46

PubMed: 25873175 ( click the link to review the publication )

Cancer Discov, 2014, 4(12):1398-405

PubMed: 25266736 ( click the link to review the publication )

Cancer Cell, 2014, 26(2):207-21

PubMed: 25065853 ( click the link to review the publication )

Nat Med, 2013, 19(11):1469-1472

PubMed: 24162815 ( click the link to review the publication )

Nature, 2012, 26;487(7408):505-9.

PubMed: 22763448 ( click the link to review the publication )

Cell, 2012, 21;151(5):937-50.

PubMed: 23178117 ( click the link to review the publication )

Nat Med, 2012, 18(6):883-91

PubMed: 22635005 ( click the link to review the publication )

Nat Med, 2011, 17(9):1116-20

PubMed: 21822287 ( click the link to review the publication )

Cancer Cell, 2011, 19(5):679-90

PubMed: 21575866 ( click the link to review the publication )

Nat Commun, 2020, 25;11(1):1556

PubMed: 32214092 ( click the link to review the publication )

Sci Adv, 2020, 22;6(21):eaaz8521

PubMed: 32494745 ( click the link to review the publication )
Dev Cell, 2020, 4;53(3):344-357 e5

PubMed: 32302545 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432.CCR-19-3608

PubMed: 32034073 ( click the link to review the publication )

Clin Cancer Res, 2020, 8

PubMed: 32269053 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432

PubMed: 32034078 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Cancers (Basel), 2020, 27;12(5)pii: E1087

PubMed: 32349331 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(2) pii: E436

PubMed: 32069833 ( click the link to review the publication )

Cancer Discov, 2020, 1 pii: CD-19-1030

PubMed: 32238360 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(2):403-423

PubMed: 32195017 ( click the link to review the publication )

Lung Cancer, 2020, 144:20-29

PubMed: 32353632 ( click the link to review the publication )

J Cell Physiol, 2020, 10.1002/jcp.29463

PubMed: 31960422 ( click the link to review the publication )

J Cell Sci, 2020, 11;133(9) pii: jcs241505

PubMed: 32184261 ( click the link to review the publication )

Antiviral Res, 2020, 178:104790

PubMed: 32272175 ( click the link to review the publication )

Int J Mol Sci, 2020, 18;21(8):2825

PubMed: 32325639 ( click the link to review the publication )

Sci Rep, 2020, 10(1):218

PubMed: 31937834 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Oncol Rep, 2020, 43(3):817-826

PubMed: 32020234 ( click the link to review the publication )

Anticancer Res, 2020, 40(1):109-119

PubMed: 31892559 ( click the link to review the publication )

Anticancer Res, 2020, 40(3):1395-1403

PubMed: 32132036 ( click the link to review the publication )

Blood Adv, 2020, 4(5):819-829

PubMed: 32126142 ( click the link to review the publication )

Mol Cancer Res, 2020, 18(4):549-559

PubMed: 31941753 ( click the link to review the publication )

J Thorac Oncol, 2020, 15(5):752-765

PubMed: 31972351 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3991

PubMed: 31488816 ( click the link to review the publication )
Nat Commun, 2019, 10(1):4343

PubMed: 31554817 ( click the link to review the publication )

Clin Cancer Res, 2019, clincanres.1486.2019

PubMed: 31636099 ( click the link to review the publication )

EMBO Mol Med, 2019, 10.15252/emmm.201910581

PubMed: 31633304 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-1667

PubMed: 31548343 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31776128 ( click the link to review the publication )

Cancer Res, 2019, 79(3):546-556

PubMed: 30538120 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-1104

PubMed: 31585938 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2331-2344

PubMed: 31461650 ( click the link to review the publication )

Cell Rep, 2019, 26(1):65-78

PubMed: 30605687 ( click the link to review the publication )

Oncogene, 2019, 101038/s41388-019-1136-4

PubMed: 31804622 ( click the link to review the publication )

Oncogene, 2019, 38(11):1936-1950

PubMed: 30390071 ( click the link to review the publication )

EBioMedicine, 2019, 42:326-339

PubMed: 30879923 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31547367 ( click the link to review the publication )

Cell Death Dis, 2019, 10(9):663

PubMed: 31506424 ( click the link to review the publication )

Cell Death Dis, 2019, 10(2):139

PubMed: 30760701 ( click the link to review the publication )

Cells, 2019, 8(12)

PubMed: 31795298 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(3):718-725

PubMed: 30755456 ( click the link to review the publication )

Front Oncol, 2019, 9:579

PubMed: 31334113 ( click the link to review the publication )

Front Oncol, 2019, 9:579

PubMed: 31380285 ( click the link to review the publication )

Cancer Sci, 2019, 110(11):3584-3594

PubMed: 31446643 ( click the link to review the publication )

Biochem Pharmacol, 2019, 166:128-138

PubMed: 31078602 ( click the link to review the publication )

Toxicol Sci, 2019, 10.1093/toxsci/kfz123

PubMed: 31132080 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(17)

PubMed: 31480591 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2019, 383:114768

PubMed: 31639374 ( click the link to review the publication )
Invest New Drugs, 2019, 10.1007/s10637-019-00795-3

PubMed: 31124056 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):1044

PubMed: 31690270 ( click the link to review the publication )

Cancer Res Treat, 2019, 51(3):1231-1240

PubMed: 30653748 ( click the link to review the publication )

Cancer Res Treat, 2019, 51(3):951-962

PubMed: 30309221 ( click the link to review the publication )

Molecules, 2019, 24(3)

PubMed: 30754629 ( click the link to review the publication )

Transl Oncol, 2019, 12(1):116-121

PubMed: 30290287 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 511(2):260-265

PubMed: 30791979 ( click the link to review the publication )

Future Oncol, 2019, 15(22):2585-2593

PubMed: 31339066 ( click the link to review the publication )

Leuk Res, 2019, 78:12-20

PubMed: 30660961 ( click the link to review the publication )

J Thorac Oncol, 2019, 14(10):1753-1765

PubMed: 31279006 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(8):768-777

PubMed: 29942081 ( click the link to review the publication )

J Clin Invest, 2018, 128(1):446-462

PubMed: 29202477 ( click the link to review the publication )

J Clin Invest, 2018, 128(9):4086-4097

PubMed: 29990309 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(13):3126-3136

PubMed: 29618618 ( click the link to review the publication )

Leukemia, 2018, 32(9):1994-2007

PubMed: 29588546 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(26):E6030-E6038

PubMed: 29875142 ( click the link to review the publication )

Cell Syst, 2018, 6(3):329-342

PubMed: 29550255 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(12):2732-2739

PubMed: 29559559 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(23):6066-6077

PubMed: 30061362 ( click the link to review the publication )

Cell Death Differ, 2018, 25(12):2053-2070

PubMed: 29515255 ( click the link to review the publication )

Sci Signal, 2018, 11(557)

PubMed: 30459283 ( click the link to review the publication )

Cell Death Dis, 2018, 9(3):262

PubMed: 29449529 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(11-:2271-2284

PubMed: 30135214 ( click the link to review the publication )
Mol Cancer Ther, 2018, 17(12):2622-2632

PubMed: 30282811 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(5):931-942

PubMed: 29440449 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(1):222-231

PubMed: 29054983 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(1):183-191

PubMed: 29416931 ( click the link to review the publication )

Mol Pharm, 2018, 15(5):1892-1900

PubMed: 29595984 ( click the link to review the publication )

Front Oncol, 2018, 8:460

PubMed: 30464927 ( click the link to review the publication )

Cancer Gene Ther, 2018, 26(1-2):1-10

PubMed: 29925897 ( click the link to review the publication )

Cancer Discov, 2018, 8(6):714-729

PubMed: 29650534 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(8):1541-1550

PubMed: 30210922 ( click the link to review the publication )

J Proteome Res, 2018, 17(1):63-75

PubMed: 29164889 ( click the link to review the publication )

Cancer Commun (Lond), 2018, 38(1):19

PubMed: 29764505 ( click the link to review the publication )

Cancer Res Treat, 2018, 50(2):599-613

PubMed: 28675026 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2018, 82(2):251-263

PubMed: 29855693 ( click the link to review the publication )

Pediatr Blood Cancer, 2018, 65(8):e27094

PubMed: 29697184 ( click the link to review the publication )

Oncol Lett, 2018, 16(5):5983-5991

PubMed: 30333869 ( click the link to review the publication )

Oncol Lett, 2018, 16(5):5992-5996

PubMed: 30333870 ( click the link to review the publication )

Oncotarget, 2018, 9(43-:27242-27255

PubMed: 29930762 ( click the link to review the publication )

Oncolytic Virother, 2018, 7:107-116

PubMed: 30538967 ( click the link to review the publication )

J Thorac Oncol, 2017, S1556-0864(17)30365-9

PubMed: 28502721 ( click the link to review the publication )

Cancer Res, 2017, 77(13):3551-3563

PubMed: 28428274 ( click the link to review the publication )

Cancer Res, 2017, 77(13):3502-3512

PubMed: 28512244 ( click the link to review the publication )

Cell Rep, 2017, 21(11):3298-3309

PubMed: 29241554 ( click the link to review the publication )

J Pathol, 2017, 243(3):307-319

PubMed: 28741662 ( click the link to review the publication )

Cell Death Dis, 2017, 8(8):e3013

PubMed: 28837150 ( click the link to review the publication )
Br J Cancer, 2017, 117(12):1787-1797

PubMed: 29024938 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2234-2245

PubMed: 28729401 ( click the link to review the publication )

Oncologist, 2017, 22(2):158-164

PubMed: 28167572 ( click the link to review the publication )

Sci Rep, 2017, 7:44206

PubMed: 28287179 ( click the link to review the publication )

Am J Cancer Res, 2017, 7(2):203-217

PubMed: 28337371 ( click the link to review the publication )

BMC Cancer, 2017, 17(1):191

PubMed: 28292264 ( click the link to review the publication )

Molecules, 2017, 22(12)

PubMed: 29206199 ( click the link to review the publication )

Medchemcomm, 2017, 8(10):1914-1918

PubMed: 30108712 ( click the link to review the publication )

Oncol Lett, 2017, 13(6):4085-4092

PubMed: 28599410 ( click the link to review the publication )

Cardiooncology, 2017, 3

PubMed: 28217366 ( click the link to review the publication )

Oncotarget, 2017, 8(70):114945-114955

PubMed: 29383132 ( click the link to review the publication )

Oncotarget, 2017, 8(35):58771-58780

PubMed: 28938595 ( click the link to review the publication )

Oncotarget, 2017, 8(31):51675-51687

PubMed: 28881678 ( click the link to review the publication )

Blood, 2016, 128(9):1234-45

PubMed: 27297792 ( click the link to review the publication )

Genome Biol, 2016, 17:80

PubMed: 27139883 ( click the link to review the publication )

Nat Commun, 2016, 7:10690

PubMed: 26891683 ( click the link to review the publication )

J Clin Invest, 2016, 3;126(10):3739-3757

PubMed: 27571409 ( click the link to review the publication )

Nat Commun, 2016, 7:11815

PubMed: 27283993 ( click the link to review the publication )

J Thorac Oncol, 2016, 11(8):1273-1281

PubMed: 27068398 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(7):1787-99

PubMed: 26667487 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(22):5527-5538

PubMed: 27780853 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(24):6031-6038

PubMed: 27091406 ( click the link to review the publication )

Cancer Res, 2016, 76(6):1506-16

PubMed: 26719536 ( click the link to review the publication )

Cancer Res, 2016, 76(13):3895-903

PubMed: 27197184 ( click the link to review the publication )
Cancer Res, 2016, 76(4):974-83

PubMed: 26837769 ( click the link to review the publication )

J Pathol, 2016, 238(4):543-9

PubMed: 26606880 ( click the link to review the publication )

Cancer Discov, 2016, 6(12):1334-1341

PubMed: 27694386 ( click the link to review the publication )

Oncoimmunology, 2016, 5(3):e1094598

PubMed: 27141355 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Int J Oncol, 2016, 49(6):2453-2463

PubMed: 27748897 ( click the link to review the publication )

Int J Oncol, 2016, 49(6):2236-2244

PubMed: 27748834 ( click the link to review the publication )

Cellular Signalling, 2016, 19;28(6):652-662

PubMed: 27006333 ( click the link to review the publication )

Endocrine, 2016, 53(1):145-56

PubMed: 26370117 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2016, 77(3):623-8

PubMed: 26849637 ( click the link to review the publication )

PLoS One, 2016, 11(11):e0165983

PubMed: 27832137 ( click the link to review the publication )

Vet Parasitol, 2016, 227:64-8

PubMed: 27523939 ( click the link to review the publication )

Int J Surg, 2016, 28:179-84

PubMed: 26957017 ( click the link to review the publication )

World J Clin Oncol, 2016, 7(6):425-432

PubMed: 28008383 ( click the link to review the publication )

Sci Rep, 2016, 10.1038/srep24817

PubMed: 27102549 ( click the link to review the publication )

Oncotarget, 2016, 7(51):84675-84687

PubMed: 27835869 ( click the link to review the publication )

Springerplus, 2016, 5:348

PubMed: 27057482 ( click the link to review the publication )

Sci Rep, 2016, 6:32992

PubMed: 27623107 ( click the link to review the publication )

Tumour Biol, 2016, 37(4):4373-82

PubMed: 26499783 ( click the link to review the publication )

Oncotarget, 2016, 7(46):75968-75980

PubMed: 27732954 ( click the link to review the publication )

Oncotarget, 2016, 7(20):29199-210

PubMed: 27078848 ( click the link to review the publication )

Oncotarget, 2016, 7(18-:25983-6002

PubMed: 27036020 ( click the link to review the publication )

Oncotarget, 2016, 7(17):23715-29

PubMed: 27009859 ( click the link to review the publication )

Blood, 2015, 126(26):2821-31

PubMed: 26531163 ( click the link to review the publication )
Cell Res, 2015, 10.1038/cr.2015.16

PubMed: 25656847 ( click the link to review the publication )

Nat Commun, 2015, 6:7002

PubMed: 25926053 ( click the link to review the publication )

Cancer Res, 2015, 10.1158/0008-5472.CAN-15-0370

PubMed: 25952648 ( click the link to review the publication )

Cancer Res, 2015, 75(14):2916-27

PubMed: 26018086 ( click the link to review the publication )

Oncoimmunology, 2015, 5(3):e1108514

PubMed: 27141364 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(11-:2433-40

PubMed: 26351321 ( click the link to review the publication )

Radiother Oncol, 2015, 114(2):173-81

PubMed: ( click the link to review the publication )

Radiother Oncol, 2015, 114(2):173-81

PubMed: ( click the link to review the publication )

Cancer Sci, 2015, 106(3):244-52

PubMed: 25581823 ( click the link to review the publication )

Lung Cancer, 2015, 90(3):590-7

PubMed: 26547802 ( click the link to review the publication )

J Cell Physiol, 2015, 230(9):2281-98

PubMed: 25704960 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2015, 285(1):51-60

PubMed: 25841593 ( click the link to review the publication )

Int J Oncol, 2015, 46(3):1025-30

PubMed: 25502629 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0124283

PubMed: 25919140 ( click the link to review the publication )

PLoS One, 2015, 10(7):e0132330

PubMed: 26147305 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0121378

PubMed: 25874976 ( click the link to review the publication )

Onco Targets Ther, 2015, 8:375-83

PubMed: 25678804 ( click the link to review the publication )

Biochem Biophys Res Commun, 2015, 10.1016/j.bbrc.2015.02.114

PubMed: 25735977 ( click the link to review the publication )

Oncotarget, 2015, 6(27):24320-32

PubMed: 26172300 ( click the link to review the publication )

Cell, 2015, 162(6):1271-85

PubMed: 26359985 ( click the link to review the publication )

Oncotarget, 2015, 6(37):40268-82

PubMed: 26384345 ( click the link to review the publication )

Zhongguo Fei Ai Za Zhi, 2015, 18(6):330-9

PubMed: 26104888 ( click the link to review the publication )

Oncotarget, 2015, 6(14):11820-32

PubMed: 25909220 ( click the link to review the publication )

Oncotarget, 2015, 6(37):40268-82

PubMed: 26384345 ( click the link to review the publication )
Oncotarget, 2015, 6(30):28774-89

PubMed: 26299615 ( click the link to review the publication )

J Thorac Oncol, 2014, 9(11):1638-46

PubMed: 25144242 ( click the link to review the publication )

J Thorac Oncol, 2014, 9(11):1638-46

PubMed: ( click the link to review the publication )

J Thorac Oncol, 2014, 9(6):775-83

PubMed: 24828661 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(11):2898-909

PubMed: 24714777 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(18):4806-15

PubMed: 25052479 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 111(44):E4706-15

PubMed: 25331893 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(11):2898-909

PubMed: 24714777 ( click the link to review the publication )

Cell Rep, 2014, 8(4):1037-48

PubMed: 25127139 ( click the link to review the publication )

Elife, 2014, 10.7554/eLife.03751

PubMed: 25551293 ( click the link to review the publication )

Cancer Lett, 2014, 351(2):215-21

PubMed: 24887559 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(1):134-43

PubMed: 24170771 ( click the link to review the publication )

Mol Cancer Ther, 2014, 10.1158/1535-7163.MCT-14-0274

PubMed: 25349307 ( click the link to review the publication )

Mol Oncol, 2014, 9(1):260-9

PubMed: 25226813 ( click the link to review the publication )

Gastric Cancer, 2014, 10.1007/s10120-014-0444-1

PubMed: 25407459 ( click the link to review the publication )

Cancer Sci, 2014, 105(5):528-36

PubMed: 24612061 ( click the link to review the publication )

Cell Cycle, 2014, 13(24):3808-17

PubMed: 25426675 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2014, 140(4):589-98

PubMed: 24509625 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2014, 74(5):1023-8

PubMed: 25205428 ( click the link to review the publication )

PLoS One, 2014, 9(11):e112148

PubMed: 25386922 ( click the link to review the publication )

PLoS One, 2014, 9(9):e105919

PubMed: 25221930 ( click the link to review the publication )

Biomed Res Int, 2014, 2014:764981

PubMed: 25057499 ( click the link to review the publication )

Biochem Biophy Res Co, 2014, 10.1016/j.bbrc.2014.10.126

PubMed: ( click the link to review the publication )

Jpn J Clin Oncol, 2014, 44(10):963-8

PubMed: 25170107 ( click the link to review the publication )
Future Oncol, 2014, 10(2):211-7

PubMed: 24490607 ( click the link to review the publication )

Leuk Res, 2014, 38(4):503-8

PubMed: 24486291 ( click the link to review the publication )

Korean J Parasitol, 2014, 52(4):439-41

PubMed: 25246725 ( click the link to review the publication )

Oncotarget, 2014, 5(13):4920-8

PubMed: 24952482 ( click the link to review the publication )

Urol Oncol, 2014, 32(6):877-84

PubMed: 24929890 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(9):2584-91

PubMed: 23515407 ( click the link to review the publication )

Int J Cancer, 2013, 133(2):427-36

PubMed: 23335077 ( click the link to review the publication )

Int J Cancer, 2013, 132(2):E74-84

PubMed: 22948846 ( click the link to review the publication )

Br J Cancer, 2013, 109(12):3084-91

PubMed: 24149177 ( click the link to review the publication )

Exp Mol Med, 2013, 45:e64

PubMed: 24263233 ( click the link to review the publication )

Mol Oncol, 2013, 7(6):1093-102

PubMed: 23993685 ( click the link to review the publication )

ACS Chem Biol, 2013, 9(3):777-84

PubMed: 24397822 ( click the link to review the publication )

J Am Heart Assoc, 2013, 2(6):e000376

PubMed: 24308935 ( click the link to review the publication )

Cancer Sci, 2013, 104(12):1640-6

PubMed: 24118504 ( click the link to review the publication )

Cancer Sci, 2013, 104(12):1618-25

PubMed: 24112719 ( click the link to review the publication )

Sci Rep, 2013, 3:3450

PubMed: 24356251 ( click the link to review the publication )

Int J Cardiol, 2013, 168(4):3486-94

PubMed: 23680593 ( click the link to review the publication )

Mol Pharmacol, 2013, 83(4):882-93

PubMed: 23371912 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2013, 272(1):245-55

PubMed: 23707608 ( click the link to review the publication )

J Cell Biochem, 2013, 114(4):816-22

PubMed: 23060267 ( click the link to review the publication )

Molecules, 2013, 18(12):15412-21

PubMed: 24335618 ( click the link to review the publication )

PLoS One, 2013, 8(12):e82236

PubMed: 24349229 ( click the link to review the publication )

PLoS One, 2013, 8(12):e84700

PubMed: 24386407 ( click the link to review the publication )

PLoS One, 2013, 8(2):e56010

PubMed: 23418494 ( click the link to review the publication )
Tumour Biol, 2013, 35(4):3229-35

PubMed: 24293393 ( click the link to review the publication )

Springerplus, 2013, 2:497

PubMed: 24102046 ( click the link to review the publication )

CELON PHARMA, 2013, 2013

PubMed: ( click the link to review the publication )

Sci Transl Med, 2012, 4(120):120ra17

PubMed: 22277784 ( click the link to review the publication )

Br J Pharmacol, 2012, 166(5):1669-83

PubMed: 22233293 ( click the link to review the publication )

Neoplasia, 2012, 14(7):572-84

PubMed: 22904675 ( click the link to review the publication )

ACS Chem Biol, 2012, 7(8):1429-35

PubMed: 22625864 ( click the link to review the publication )

J Biol Chem, 2012, 287(18):14586-97

PubMed: 22418436 ( click the link to review the publication )

J Biol Chem, 2012, 287(47):39812-23

PubMed: 23024367 ( click the link to review the publication )

PLoS One, 2012, 7(2):e30820

PubMed: 22319590 ( click the link to review the publication )

Pediatr Blood Cancer, 2012, 17(23):7394-401

PubMed: 22488797 ( click the link to review the publication )

Clin Cancer Res, 2011, 59(3):440-7

PubMed: 21948233 ( click the link to review the publication )

Cancer Res, 2011, 71(15):5255-64

PubMed: 21697284 ( click the link to review the publication )

J Biomol Screen, 2011, 16(2):141-54

PubMed: 21297102 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

产品安全说明书

c-Met抑制剂选择性比较

生物活性

产品描述

靶点

ROS1 ^[6] (Cell-free assay)	c-Met ^[1] (A549, MDA-MB-231, GTL-16, HT29, 786-O, Colo-205, A498 cells)	ALK ^[1] (Karpas299 cells)
<0.025 nM(Ki)	11 nM	24 nM

体外研究

PF-2341066作用于mIMCD3小鼠和MDCK犬上皮细胞，作用于c-Met磷酸化作用时具有相似效果，IC50分别为5 nM 和20 nM。PF-2341066作用于表达c-Met ATP-结合位点突变型V1092I 或H1094R或 P-环突变 M1250T 的NIH3T3 细胞，具有相似的活性，且活力增高，IC50分别为19 nM,2 nM 和15 nM,而作用于表达野生型受体的NIH3T3 细胞时，IC50为13 nM。^[1] 相反, 观察到PF-2341066作用于表达c-Met活化环突变型Y1230C 和Y1235D的细胞时，与作用于野生型受体相比，效果发生显著改变，IC50分别为127 nM 和92 nM。PF-2341066 作用于分别表达内源性c-Met 突变体R988C和 T1010I 的NCI-H69 和HOP92 细胞，也有效抑制c-Met 磷酸化, IC50分别为13 nM 和16 nM。与作用于c-Met相比，PF-2341066作用于VEGFR2 和PDGFRβ RTKs, 选择性高1000多倍，作用于IRK和Lck选择性高250多倍，作用于Tie2, TrkA,和TrkB选择性高40到60倍。PF-2341066 作用于RON和 Axl RTKs时选择性为20到30倍。相反，PF-2341066 作用于表达ALK RTK 的核磷蛋白 (NPM)- 间变性淋巴瘤激酶(ALK) 致癌融合突变体和 KARPAS299人间变性大细胞淋巴瘤(ALCL)细胞系时具有相近的IC50值，为24 nM。PF-2341066抑制c-Met依赖的癌细胞的肿瘤表现型，和内皮细胞的血管生成表现型。PF-2341066抑制人GTL-16胃癌细胞生长，IC50为9.7 nM。PF-2341066诱导 GTL-16细胞凋亡，IC50 为8.4 nM。PF-2341066 抑制HGF刺激的人NCI-H441肺癌细胞迁移和入侵，IC50分别为11 nM 和6.1 nM。PF-2341066抑制 MDCK细胞散射，IC50为16 nM。PF-2341066 抑制HGF-刺激的c-Met磷酸化,细胞存活，和Matrigel入侵，IC50分别为11 nM, 14 nM和35 nM。此外, PF-2341066抑制纤维蛋白胶中的血清刺激的 HMVEC分支小管形成 (形成血管)。^[1] PF-2341066 作用于Karpas299 或SU-DHL-1 ALCL细胞，也有效抑制 NPM-ALK磷酸化，IC50 为24 nM。PF-2341066 有效抑制细胞增殖，伴随着使细胞周期停在G(1)-S期，且诱导 ALK阳性的 ALCL 细胞凋亡，IC50为30 nM, 但是作用于ALK阴性的淋巴瘤细胞则无效果。 ^[2] 此外, PF-2341066 抑制骨肉瘤的一些活动行为，及其肿瘤生长 (例如,增殖和存活)和转移 (例如，入侵和形成克隆)。^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
BAF3	MmrLR5l1d3SxeHnjJGF{e2G7		NWfqW2NOPDhiaB?=	M2PEU2ROW09?	MoXsR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmFHOyClZXzsd{BmgHC{ZYPzbY5oKEGOSzDGNVE4PExibYX0ZY51KGOxZYjwdoV{e2mwZzDFUWw1KHerdHigTWM2OCCxZjCwMlYzKM7:TR?=	M1zYU\|IyPTd{NUi5
BAF3	NGL2UnBEgXSxdH;4bYMhSXO\|YYm=		NFjteJQ1QCCq	M4DGNWROW09?	M1HUPGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCTjNiY3XscJMh\XiycnXzd4lv\yCDTFugUFEyQT[PIH31eIFvfCClb3X4dJJme3OrbnegSW1NPCC5aYToJGlEPTBib3[gNk4zKM7:TR?=	MVWyNVU4OjV6OR?=
BAF3	MVLDfZRwfG:6aXOgRZN{[Xl?		M1fRZ\|Q5KGh?	MX;EUXNQ	MkjYR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmFHOyClZXzsd{BmgHC{ZYPzbY5oKEWPTEStRWxMKHerdHigTWM2OCCxZjCwMlI5KM7:TR?=	Mln4NlE2PzJ3OEm=
Kelly	NI[wc3pEgXSxdH;4bYMhSXO\|YYm=			MVfEUXNQ	NGTEdXpEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBM\WyueTDj[YxteyCneIDy[ZN{cW6pIFHMT{BHOTF5NFygcZV1[W62IIfpeIghUUN3MDDv[kAxNjR{IN88US=>	NEXNSpQzOTV5MkW4PS=>
SH-SY5Y	MXXDfZRwfG:6aXOgRZN{[Xl?			NIPqS\|RFVVOR	NUToVGxGS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0hvU2m1XUBk\WyuczDlfJBz\XO\|aX7nJGFNUyCIMUG3OGwhdXW2YX70JJdqfGhiSVO1NEBw\iByLkWzJO69VQ>?	M4DDVFIyPTd{NUi5
SMS-KCN	NGPHTFJEgXSxdH;4bYMhSXO\|YYm=			M3r1dWROW09?	M3H3WGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNOWy2NQ16gZ4VtdHNiZYjwdoV{e2mwZzDBUGshWjF{N{XRJI12fGGwdDD3bZRpKEmFNUCgc4YhOC57MTFOwG0>	M3rUSFIyPTd{NUi5
BAF3	M1zoemN6fG:2b4jpZ{BCe3OjeR?=		NFnBWmk1QCCq	NFLWZ2FFVVOR	NWPRWWNTS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhSkGIMzDj[YxteyCneIDy[ZN{cW6pIGTlcE1CVEtid3n0bEBKSzVyIH;mJFAvOTlizszN	MljvNlE2PzJ3OEm=
3T3	NXS4cnpMTnWwY4Tpc44hSXO\|YYm=		NVrTdJdbOSCq	M3jVN2ROW09?	NF[zSIlKdmirYnn0bY9vKG:oIGLPUkBie3Onc4Pl[EBieyCpcn;3eIgh\mGldH;yMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wPEDPxE1?	MXSyNVgyOjRzNB?=
3T3-E	NETZclFHfW6ldHnvckBCe3OjeR?=		MUKxJIg>	M3\HSmROW09?	NG\kcYdKdmirYnn0bY9vKG:oIGTJSVIh[XO\|ZYPz[YQh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:\|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwNES4JO69VQ>?	M{O1VlIyQDF{NEG0
A549	NH:4enBMcW6jc3WgRZN{[Xl?		MoT6NUBp	NHuwZ2hFVVOR	MoLOTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCClLV3FWEBscW6jc3Wg[ZhxemW\|c3XkJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gTGdHNWmwZIXj[YQh[XW2b4Doc5NxcG:{eXzheIlwdiC5aYToJGlEPTBib3[gNE4xODhizszN	MX:yNVgyOjRzNB?=
BAF3-BCL	MnzDSpVv[3Srb36gRZN{[Xl?		M1jYdlEhcA>?	NFS1SHVFVVOR	M17jbGlvcGmkaYTpc44hd2ZiQVLMJIF{e2W\|c3XkJIF{KGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iBzLkG1PUDPxE1?	NH\Cc\|gzOThzMkSxOC=>
HEK293	NX;MTJZMTnWwY4Tpc44hSXO\|YYm=		NEj5d3gyKGh?	NFz4UmdFVVOR	MlSzTY5pcWKrdHnvckBw\iCDWFygZZN{\XO\|ZXSgZZMh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:\|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMkm0JO69VQ>?	MXqyNVgyOjRzNB?=
HEK293	NXz6dpRUTnWwY4Tpc44hSXO\|YYm=		NFvuT5gyKGh?	NEDZZVRFVVOR	Mn7tTY5pcWKrdHnvckBw\iCLUjDhd5Nme3OnZDDhd{Boem:5dHig[oFkfG:{LXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOi56OEeg{txO	MWqyNVgyOjRzNB?=
Jurkat	NXj4SIVYTnWwY4Tpc44hSXO\|YYm=		NX\yUYJSOSCq	MmXzSG1UVw>?	NVnuUmhZUW6qaXLpeIlwdiCxZjDMR2sh[XO\|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR\|UxKG:oIEKuO\|QyKM7:TR?=	NW[4OGxtOjF6MUK0NVQ>
KARPAS299	Mn7XT4lv[XOnIFHzd4F6		NVruTIdnOSCq	MmL0SG1UVw>?	Mn34TY5pcWKrdHnvckBw\iCDTFugZZN{\XO\|ZXSgZZMh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:\|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMEKg{txO	MVGyNVgyOjRzNB?=
PAE	NVTPbZV[TnWwY4Tpc44hSXO\|YYm=		M4PTe\|EhcA>?	NI\mNnpFVVOR	M2SyfWlvcGmkaYTpc44hd2ZiVGLLRkBie3Onc4Pl[EBieyCpcn;3eIgh\mGldH;yMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6zPVkh\|ryP	NXPjdmVKOjF6MUK0NVQ>
BAF3	MVrGeY5kfGmxbjDBd5NigQ>?		MkTZNk0{KGR?	NEPvTINFVVOR	NI[4UXBKdmirYnn0bY9vKG:oIGTFUE1nfXOnZDDpcpN2dGmwIILlZ4VxfG:{IHX4dJJme3OnZDD3bZRpKEmFNUCgc4YhOS54NEOg{txO	NUnNUVR7OjN5NEKyOVI>
KARPAS299	NFKyOXpEgXSxdH;4bYMhSXO\|YYm=		NV3KOodHOi1\|IHS=	NIWzdlVFVVOR	MXnJR\|UxRTBwME[0NkDPxE1?	NH\YcpkzOzd2MkK1Ni=>
EBC1	NV;4PGluT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYS3NkBp	MnPPSG1UVw>?	MmXGTWM2OD1yLkCyN{DPxE1?	NUTyZVlzOjN7OUOzNlg>
HCT116	NYPZXpA2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmXyO\|IhcA>?	MWHEUXNQ	MUTJR\|UxRTF2LkiyJO69VQ>?	M4C2dVI{QTl\|M{K4
MCF7	NXm4S\|d6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWPXUpZ1PzJiaB?=	NEPwbY9FVVOR	Ml7HTWM2OD17LkW4JO69VQ>?	Mlf1NlM6QTN\|Mki=
MDA-MB-231	NXP1blVbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MlfvO\|IhcA>?	Mmj3SG1UVw>?	MofDTWM2OD1zMD64JO69VQ>?	Mn;yNlM6QTN\|Mki=
MKN45	NWjTUFd[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWH6emp5PzJiaB?=	M3LzdWROW09?	MX7JR\|UxRTBwMEGzJO69VQ>?	NVfYUlB2OjN7OUOzNlg>
NCI-H441	NVLUcmI4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWjycY1YPzJiaB?=	NXPJPW96TE2VTx?=	M4LlOGlEPTB;MUeuNlUh\|ryP	M2f6WVI{QTl\|M{K4
NCI-H661	NUnOOZB{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MlXOO\|IhcA>?	MULEUXNQ	MYXJR\|UxRTFzLkS3JO69VQ>?	MY[yN\|k6OzN{OB?=
SK-MEL-28	M3PnOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGrwbW44OiCq	MUPEUXNQ	MnzsTWM2OD1zMD65O{DPxE1?	NF72N\|AzOzl7M{OyPC=>
SKOV3	M1K3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MlyyO\|IhcA>?	NF7F[2hFVVOR	NY\0U2ltUUN3ME2xNk45PSEQvF2=	NXP0W41QOjN7OUOzNlg>
SNU5	NYXlRWVET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NIj4cJA4OiCq	NUjX[ZdnTE2VTx?=	NWO5UJE1UUN3ME2wMlAyPiEQvF2=	NF:5RmgzOzl7M{OyPC=>
NCI-H2228	MoDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NV7kZ3NrPzJiaB?=	MVTEUXNQ	Mon3TY5pcWKrdHnvckBw\iCDTFut[pV{cW:wIHTybZZmdiClZXzsJJBzd2yrZnXyZZRqd25id3n0bEBKSzVyIH;mJFAvOTF6IN88US=>	Ml3wNlQ1OzJ7MEm=
NCI-H3122	NG\E[4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHvRVo04OiCq	NWm3WpVRTE2VTx?=	Mo\MTY5pcWKrdHnvckBw\iCDTFut[pV{cW:wIHTybZZmdiClZXzsJJBzd2yrZnXyZZRqd25id3n0bEBKSzVyIH;mJFAvOTB6IN88US=>	MWeyOFQ{OjlyOR?=
NCI-H3122	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVK3NkBp	MUnEUXNQ	MVrJcohq[mm2aX;uJI9nKEGOSz3meZNqd25iZILpeoVvKGOnbHygdJJwdGmoZYLheIlwdiCrbjDoeY1idiCQQ1mtTFMyOjJiY3XscJMhcGG{Yn;ybY5oKEGOSzDHNVI3QUFibYX0ZY51KHerdHigTWM2OCCxZjCwMlYzOyEQvF2=	NGTGOG4zPDR\|MkmwPS=>
NCI-H3122	M2nqcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWT1bpROPzJiaB?=	NV7pXnFRTE2VTx?=	MmnvTY5pcWKrdHnvckBw\iCDTFut[pV{cW:wIHTybZZmdiClZXzsJJBzd2yrZnXyZZRqd25iaX6gbJVu[W5iTlPJMWg{OTJ{IHPlcIx{KGijcnLvdolv\yCDTFugUFEyQT[PIH31eIFvfCC5aYToJGlEPTBib3[gNE45OzhizszN	MnjlNlQ1OzJ7MEm=
NIH-3T3	M3Xlc2tqdmG\|ZTDBd5NigQ>?		NE\W[oEyKGh?	NIrPToVFVVOR	MV3Jcohq[mm2aX;uJI9nKGi3bXHuJJdqdGRidInw[UBGVUx2LX\1d4VlKEGOSzDlfJBz\XO\|ZXSgZZN{\XO\|ZXSgZZMheGixc4Doc5J6dGG2ZXSgRWxMKGyndnXsJJdqfGhiSVO1NEBw\iByLkC4JO69VQ>?	NET6WWQzPDR\|MkmwPS=>
NIH-3T3	NHvB[FZMcW6jc3WgRZN{[Xl?		NYPj[GJGOSCq	M1HpOWROW09?	NVKydIdbUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BIOTJ4OVGgcZV1[W62IHX4dJJme3OnZDDhd5Nme3OnZDDhd{BxcG:\|cHjvMWFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMD62NFUh\|ryP	M{HSeVI1PDN{OUC5
NIH-3T3	Ml;GT4lv[XOnIFHzd4F6		MnH0NUBp	NGezfZlFVVOR	NH;MS2JKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJHMyOjB4WTDteZRidnRiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJJBpd3OyaH:tRWxMKGyndnXsJJdqfGhiSVO1NEBw\iByLk[yOkDPxE1?	MoDFNlQ1OzJ7MEm=
NIH-3T3	MlT2T4lv[XOnIFHzd4F6		MX2xJIg>	NWXRN5p[TE2VTx?=	MUTJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIFyxNVk3VSCvdYThcpQh\XiycnXzd4VlKGG\|c3Xzd4VlKGG\|IIDoc5NxcG9vQVzLJIxmfmWuIIfpeIghUUN3MDDv[kAxNjh2MzFOwG0>	MlHHNlQ1OzJ7MEm=
NIH-3T3	NFLifpVMcW6jc3WgRZN{[Xl?		NHLPbZEyKGh?	NX\6XVNVTE2VTx?=	Ml7jTY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDMNVE2OlJibYX0ZY51KGW6cILld5Nm\CCjc4Pld5Nm\CCjczDwbI9{eGixLVHMT{Bt\X[nbDD3bZRpKEmFNUCgc4YhOS5yMk[g{txO	MYeyOFQ{OjlyOR?=
BAF3	M3z4bGZ2dmO2aX;uJGF{e2G7		MVy3NkBp	MXjEUXNQ	NFnrTXBKdmirYnn0bY9vKG:oIF7QUU9CVEtidILhcpNn\WO2ZXSgZZN{\XO\|ZXSgZZMh[2WubDDndo94fGhiaX7obYJqfGmxbjD3bZRpKEmFNUCgc4YhOC5yNUGg{txO	MYqyOFQ3QDZ\|Mh?=
BAF3	M3z0eGN6fG:2b4jpZ{BCe3OjeR?=		MXG3NkBp	MVzEUXNQ	NFvPc2JKSzVyPUCuPVgh\|ryP	MnrNNlQ1Pjh4M{K=
NIH-3T3	MnjFT4lv[XOnIFHzd4F6		NXX4[JZMOSCq		MWXJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIF[xNVc1VCCvdYThcpQh\XiycnXzd4VlKGG\|c3Xzd4VlKGG\|IIDoc5NxcG9vQVzLJIxmfmWuIIfpeIghUUN3MDDv[kAxNjF4NTFOwG0>	NULZSXVkOjR6MUmxNVY>
NIH-3T3	MV3LbY5ie2ViQYPzZZk>		NEW1cXEyKGh?		NUHMW\|NiUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BEOTF3NmmgcZV1[W62IHX4dJJme3OnZDDhd5Nme3OnZDDhd{BxcG:\|cHjvMWFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMD60O\|gh\|ryP	NFj5NXQzPDhzOUGxOi=>
NIH-3T3	NVLxOJBuU2mwYYPlJGF{e2G7		NHvlNZgyKGh?		MY\Jcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIFexNlAzWiCvdYThcpQh\XiycnXzd4VlKGG\|c3Xzd4VlKGG\|IIDoc5NxcG9vQVzLJIxmfmWuIIfpeIghUUN3MDDv[kAyNjF2ODFOwG0>	MXWyOFgyQTFzNh?=
NIH-3T3	NUTKU3E5U2mwYYPlJGF{e2G7		NF3KdnoyKGh?		MXzJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIEGxOVFVcW6\|IH31eIFvfCCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgdIhwe3Cqbz3BUGshdGW4ZXyge4l1cCCLQ{WwJI9nKDNwMEO5JO69VQ>?	MnO4NlQ5OTlzMU[=
KARPAS299	NVzUVnFJU2mwYYPlJGF{e2G7		NXL3WZlSQTBibXnu	NHzHVYxFVVOR	MmiwTY5pcWKrdHnvckBw\iCQUF2t[pV{\WRiQVzLJJBpd3OyaH;yfYxifGmxbjDlfJBz\XO\|ZXSge4l1cCCLQ{WwJI9nKDBwMUGg{txO	M13iZ\|I1QTByN{Ww
MKN 45	M1fYPWtqdmG\|ZTDBd5NigQ>?		NH3SUYYyKGh?	M4TnfWROW09?	MnviTY5pcWKrdHnvckBw\iClLV3leEBxcG:\|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMEKg{txO	NFXB[nozPDlyMEe1NC=>
A549	MnjUR5l1d3SxeHnjJGF{e2G7		MU[0PEBp	M4jQWmROW09?	NGnsOZFKSzVyIH;mJFQvODh2IN88US=>	MVSyOFkxODh\|MB?=
NCI-H1975	NFXEXopEgXSxdH;4bYMhSXO\|YYm=		MmHHOFghcA>?	MXrEUXNQ	M4jVdmlEPTBib3[gO{42PTFizszN	NYjYNXl[OjR7MEC4N\|A>
NCI-H1993	MkS4R5l1d3SxeHnjJGF{e2G7		NUfIN\|c6PDhiaB?=	NUTKS4RJTE2VTx?=	MXzJR\|UxKG:oIECuNFYyKM7:TR?=	MUiyOFkxODh\|MB?=
NCI-H1993	NV;DVo9wSXCxdH;zbZMhSXO\|YYm=	NWn1Oo1XOSEQvF2=	NVL0VXRzOjRiaB?=	NF7oVWFFVVOR	M{LnN4Rw\XNibn;0JIlv\HWlZTDhdI9xfG:\|aYO=	NWD1ToZWOjR7MEC4N\|A>
NIH-3T3	MXHDfZRwfG:6aXOgRZN{[Xl?		NEj0RpY1QCCq	MV7EUXNQ	MYPJR\|UxKG:oIECuN\|Y1KM7:TR?=	M1eyU\|I1QTByOEOw
EBC1	M3;rbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M335O\|czKGh?	MXfEUXNQ	MoXlTWM2OCCxZjCwMlAxPjlizszN	MmrhNlQ6ODB6M{G=
KARPAS299	NXPwbmtOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MXy3NkBp	NEPJ[mZFVVOR	MXTJR\|UxKG:oIECuNkDPxE1?	NGe5cYUzPDlyMEizNS=>
NB1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlOwTWM2OD17MT65PEBvVQ>?	MW\TRW5ITVJ?
NCI-SNU-5	M3PyWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVvJR\|UxRTFyNT63OUBvVQ>?	NFPhcYdUSU6JRWK=
SR	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVjxOW1IUUN3ME2xNlYvOzFibl2=	NVTKcnBmW0GQR1XS
SF539	NGLBVJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVPJR\|UxRTJyND6yOEBvVQ>?	M1\FUnNCVkeHUh?=
SU-DHL-1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4\QN2lEPTB;M{O2MlgzKG6P	MlvIV2FPT0WU
SCC-3	Mn;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYnJR\|UxRTN3Nj63OkBvVQ>?	NUXuRXdPW0GQR1XS
DEL	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnLxTWM2OD1\|NkmuPUBvVQ>?	MVTTRW5ITVJ?
CTV-1	NF31PGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUTJR\|UxRTV7Nj60PEBvVQ>?	MnXsV2FPT0WU
EM-2	M4q1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVLJR\|UxRTZyMT6zOEBvVQ>?	NUW0XodUW0GQR1XS
MHH-CALL-2	MmHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHriRYlKSzVyPU[4Nk42PyCwTR?=	MXHTRW5ITVJ?
KM12	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2mybGlEPTB;N{C2Mlkhdk1?	Mnf0V2FPT0WU
KINGS-1	NFLrc2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2joS2lEPTB;N{S5Mlc2KG6P	NVHpclljW0GQR1XS
MEG-01	M2LaWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3niNmlEPTB;OEW3MlY3KG6P	NXTCOlNtW0GQR1XS
BV-173	NYPOWplST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHHmZXpKSzVyPUGuNFU6QTdizszN	MX3TRW5ITVJ?
LAMA-84	M3vTR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFj4SYNKSzVyPUGuN\|gzQDJizszN	NE\RTI5USU6JRWK=
KARPAS-299	MnH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEjGN2pKSzVyPUGuOFA5PjFizszN	NIn2PWxUSU6JRWK=
K-562	NXnabmtUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXO5N2VxUUN3ME2xMlczOjZ7IN88US=>	NFvZOm9USU6JRWK=
SK-LMS-1	NFPVXFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4DSSWlEPTB;MT63Olg3PyEQvF2=	NGLFTGVUSU6JRWK=
MOLT-16	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml7wTWM2OD1zLkm1OVc2KM7:TR?=	NEfkXmNUSU6JRWK=
CMK	MmDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoC0TWM2OD1zLkm2NVU6KM7:TR?=	NFjxPI9USU6JRWK=
ST486	MnXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVzJR\|UxRTJwNEOwO\|Mh\|ryP	Mmq1V2FPT0WU
CI-1	NGi4eYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGrpXGtKSzVyPUKuOFk3PTlizszN	M3nJWnNCVkeHUh?=
KP-N-RT-BM-1	M2njTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M17HdGlEPTB;Mj63NFEzOiEQvF2=	NUSxXHNQW0GQR1XS
ALL-PO	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2n1NWlEPTB;Mz6xPFIxPyEQvF2=	MVvTRW5ITVJ?
KS-1	Ml3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MU\JR\|UxRTNwMkGyNlUh\|ryP	MWTTRW5ITVJ?
Becker	MoHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MW\JR\|UxRTRwMkO5N{DPxE1?	MYXTRW5ITVJ?
GDM-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGHUbmFKSzVyPUSuNlQ3OTdizszN	NGfOXIxUSU6JRWK=
BC-1	NF:0N3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWnlNYxyUUN3ME20MlQ6Ojd5IN88US=>	M1TiRnNCVkeHUh?=
NB14	NH;BblhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{fafmlEPTB;ND64N\|UzPCEQvF2=	M1jycXNCVkeHUh?=
NOS-1	MkPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFezfXJKSzVyPUWuN\|M5PzRizszN	NXPTO2c4W0GQR1XS
MZ1-PC	NVPCT3VPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1TsZ2lEPTB;NT64NlE2OSEQvF2=	M{XZOnNCVkeHUh?=
A498	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVXJR\|UxRTZwMEi0O\|Mh\|ryP	NWOzV25yW0GQR1XS
EW-16	Ml7IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVrJR\|UxRTZwM{e3O\|Mh\|ryP	MlHqV2FPT0WU
NALM-6	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mni3TWM2OD14Lk[4N\|g4KM7:TR?=	MkPZV2FPT0WU
EB-3	NITaSFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV3JR\|UxRTdwMEeyN\|Mh\|ryP	NF\2c4FUSU6JRWK=
697	MoPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmW5TWM2OD17LkK0N\|I6KM7:TR?=	MWfTRW5ITVJ?
Ramos-2G6-4C10	Mn;nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn:1TWM2OD17LkW5PFQzKM7:TR?=	MVLTRW5ITVJ?
KNS-81-FD	NWfYTXVJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIPGfYhKSzVyPUmuOlk3PTNizszN	MY\TRW5ITVJ?
HUTU-80	NWHtXo5YT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEPrV5JKSzVyPUmuO\|Q3PDJizszN	NVPDXXR3W0GQR1XS
LS-411N	M3zZXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWX1e25ZUUN3ME2xNE4xPTZ5IN88US=>	NFeyTWRUSU6JRWK=
RPMI-8402	MkXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEe3W2tKSzVyPUGwMlEyPiEQvF2=	MlTOV2FPT0WU
KU812	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWjJR\|UxRTFyLkK5PVEh\|ryP	MoTSV2FPT0WU
EW-1	M3jQ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVHJR\|UxRTFyLkS0NlUh\|ryP	NHnmTnhUSU6JRWK=
HC-1	NHPUOGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYrEZlNGUUN3ME2xNE41QDR2IN88US=>	M3zLVnNCVkeHUh?=
NB69	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGqyPWtKSzVyPUGwMlUxPDNizszN	Mor3V2FPT0WU
MFH-ino	NFS0UoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVXsOpJbUUN3ME2xNE45OzB\|IN88US=>	MmHTV2FPT0WU
CCRF-CEM	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVe1fItbUUN3ME2xNU42QTdizszN	MonzV2FPT0WU
SK-N-DZ	NGDEN\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVvJR\|UxRTF{LkC0N\|Yh\|ryP	NXzWWmJDW0GQR1XS
NCI-H720	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlzmTWM2OD1zMj6xO\|A2KM7:TR?=	NHvzW49USU6JRWK=
HCC1187	M2XBTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYC2ZnRjUUN3ME2xNk4zODRzIN88US=>	NWLEdmJOW0GQR1XS
IST-SL2	M{m2cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1;tVmlEPTB;MUKuOFg4OiEQvF2=	MmfiV2FPT0WU
KE-37	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXv3TIpTUUN3ME2xNk44QTZ4IN88US=>	MlnJV2FPT0WU
HCC1599	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{DhNmlEPTB;MUKuPVA3QSEQvF2=	M4CzXXNCVkeHUh?=
A4-Fuk	M{fweGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX7JR\|UxRTF{Lkm1PFYh\|ryP	NVzObFZHW0GQR1XS
NKM-1	NIfQNWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVzLOm9IUUN3ME2xN{4zQTJ3IN88US=>	NH7MZYxUSU6JRWK=
BE-13	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX\JR\|UxRTF\|Lke5PFkh\|ryP	MYDTRW5ITVJ?
MV-4-11	MmnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{TYbmlEPTB;MUSuNFMzPCEQvF2=	NGK5eXpUSU6JRWK=
OPM-2	M4X0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{LJPWlEPTB;MUSuOFA5PSEQvF2=	NXnwW2tDW0GQR1XS
KARPAS-422	Ml\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVrJR\|UxRTF2LkWxNlYh\|ryP	MYTTRW5ITVJ?
RPMI-8226	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTF2Lki5NVUh\|ryP	NGHDfVlUSU6JRWK=
KARPAS-45	Mo\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlziTWM2OD1zNT63O\|E3KM7:TR?=	MoX2V2FPT0WU
SK-PN-DW	NWDRVWFlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX3JR\|UxRTF3Lki2N\|Eh\|ryP	MWjTRW5ITVJ?
LC-2	Mn3jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MljHTWM2OD1zNj6xOVA3KM7:TR?=	MmHEV2FPT0WU
NCI-H1648	M1fSTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYHLOY1pUUN3ME2xOk4zPTRizszN	M{HwV3NCVkeHUh?=
RL95-2	NEH3epVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mkf4TWM2OD1zNj6zPVc5KM7:TR?=	Mk\WV2FPT0WU
KNS-42	NWPzU3ZPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTF4LkeyO\|Qh\|ryP	M{jhVXNCVkeHUh?=
RPMI-6666	NXfMSGxrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4Hs[mlEPTB;MU[uPVIyOSEQvF2=	MYrTRW5ITVJ?
SIG-M5	M13UVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHrrdVFKSzVyPUG3MlE6ODNizszN	NIXyd2ZUSU6JRWK=
VA-ES-BJ	M{XyPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVzGUlZ1UUN3ME2xO{44PDVzIN88US=>	NXzHTYlYW0GQR1XS
MONO-MAC-6	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXG5T45JUUN3ME2xO{46OzF{IN88US=>	MYDTRW5ITVJ?
LAN-6	NVO3XlZtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{\kXmlEPTB;MUiuO\|U2PyEQvF2=	M4C5TXNCVkeHUh?=
A388	M2LYUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXTJR\|UxRTF7LkOwOVkh\|ryP	NYXYeHFiW0GQR1XS
SK-NEP-1	NEfr[pdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mom4TWM2OD1{MD6yNVMzKM7:TR?=	NH;oUFRUSU6JRWK=
TE-10	NECxbmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYDxUJlUUUN3ME2yNE42OjJzIN88US=>	Ml\MV2FPT0WU
HL-60	NV;JU3JWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUjJR\|UxRTJyLkmwPVkh\|ryP	MkHSV2FPT0WU
MC116	NYfRNnJlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2nNR2lEPTB;MkGuO\|IzOSEQvF2=	M{[yW3NCVkeHUh?=
SW962	NXjZR\|lbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3;YSmlEPTB;MkGuO\|kyPSEQvF2=	MoPCV2FPT0WU
NOMO-1	MmrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV;GOI9CUUN3ME2yNk43PTZ2IN88US=>	NXuwZXNHW0GQR1XS
CTB-1	MnzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnjHTWM2OD1{Mj64OlcyKM7:TR?=	NIjS[FdUSU6JRWK=
MRK-nu-1	MoHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1W2c2lEPTB;MkKuPVA4PCEQvF2=	MojQV2FPT0WU
GR-ST	NVzJSIhyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUPVT5o4UUN3ME2yN{44PiEQvF2=	MoTEV2FPT0WU
HH	M1nkRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYjJR\|UxRTJ2LkCwN{DPxE1?	MXfTRW5ITVJ?
NCI-H1963	NI\3fXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXPweYZTUUN3ME2yOE4xPzh{IN88US=>	MUHTRW5ITVJ?
QIMR-WIL	NHHzco9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVT5O4d2UUN3ME2yOE45Pzd{IN88US=>	NWLTU4d6W0GQR1XS
CGTH-W-1	M{PneWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NInlPGZKSzVyPUK1MlA4OjNizszN	NE\oWIlUSU6JRWK=
LP-1	NHrWOJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVHJR\|UxRTJ3Lk[1OVEh\|ryP	M2DBSXNCVkeHUh?=
NCI-H748	NWrUW\|ZxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV;JR\|UxRTJ4LkWxN\|ch\|ryP	NIT3[4VUSU6JRWK=
PF-382	M4SySmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYjJR\|UxRTJ5LkKyNlMh\|ryP	NFf0ZWxUSU6JRWK=
ATN-1	M2K3cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYjJR\|UxRTJ5LkO3N\|Ih\|ryP	MojpV2FPT0WU
L-540	NWe2UokzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHjN[pJKSzVyPUK3MlY1PTlizszN	MnnWV2FPT0WU
LXF-289	MmjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXLYWlhsUUN3ME2yO{44PTF7IN88US=>	NGTmelRUSU6JRWK=
LS-513	NW\wd4I1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVfNTYZyUUN3ME2yPE4yQDB5IN88US=>	MofNV2FPT0WU
NCI-H1581	M4jNbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MojuTWM2OD1\|MD6zPVc3KM7:TR?=	MXrTRW5ITVJ?
ES6	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3\Ue2lEPTB;M{CuOlg6QSEQvF2=	NU\Dbo84W0GQR1XS
SW982	M1nrcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3LvW2lEPTB;M{CuPFU3PiEQvF2=	NIr5W41USU6JRWK=
DOHH-2	M17OUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV3JR\|UxRTNzLkW4PVMh\|ryP	NEfXbXZUSU6JRWK=
DB	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUfJR\|UxRTN\|Lkm0N\|Eh\|ryP	NFHabZNUSU6JRWK=
MPP-89	M1PYbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXLJR\|UxRTN2LkG3OVYh\|ryP	M4TtV3NCVkeHUh?=
LB831-BLC	NHexNoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NETLW3hKSzVyPUO0MlUyQDRizszN	M1rMZnNCVkeHUh?=
NB5	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU\mUJllUUN3ME2zOE45PTN3IN88US=>	MXPTRW5ITVJ?
GB-1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NY[5R2lwUUN3ME2zOU4xPDZ7IN88US=>	NXjzRXRSW0GQR1XS
TE-15	NEiySFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm\KTWM2OD1\|NT6yNlM5KM7:TR?=	M4ewUXNCVkeHUh?=
LC4-1	MoXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2fiVmlEPTB;M{WuN\|g1PyEQvF2=	NYjVVmNMW0GQR1XS
NCI-H747	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoXHTWM2OD1\|Nj6xN\|Y6KM7:TR?=	NVq1RYlKW0GQR1XS
NTERA-S-cl-D1	M2\hZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRTN6LkezOFch\|ryP	NUjGSJRSW0GQR1XS
SK-MM-2	NGXETZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnH0TWM2OD12MD6xNVQ3KM7:TR?=	MnPMV2FPT0WU
TGW	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3:1e2lEPTB;NEGuNFU3OyEQvF2=	M{TuUHNCVkeHUh?=
ONS-76	MmPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFTMVoRKSzVyPUSyMlQ5QDNizszN	MmiyV2FPT0WU
CPC-N	M4TQ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXrJR\|UxRTR{Lkm5O\|Eh\|ryP	NYTSWnBUW0GQR1XS
ES4	NIfSfZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV;JR\|UxRTR2LkSxOVMh\|ryP	MnrMV2FPT0WU
Daudi	NF[zNnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXPjfIF6UUN3ME20OU4xQDJ5IN88US=>	NXW4VYdXW0GQR1XS
MOLT-4	M4jRO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXS2OmE3UUN3ME20OU4xQDV\|IN88US=>	M4\JdnNCVkeHUh?=
HT-144	MmfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4S4VmlEPTB;NE[uO\|I3KM7:TR?=	MmmxV2FPT0WU
SW872	NFHPXXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{fydWlEPTB;NEiuNVk{OyEQvF2=	Mmq3V2FPT0WU
D-283MED	Mn3oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX;JR\|UxRTR6LkO1OFIh\|ryP	M2XWVnNCVkeHUh?=
NCI-H2126	NIG2SpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTR6Lki0O\|Yh\|ryP	MVTTRW5ITVJ?
NCI-SNU-16	NGDRfGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYH2eXlmUUN3ME20PU4zOTR\|IN88US=>	M4q5[XNCVkeHUh?=
CESS	NHuxfJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4DpVmlEPTB;NEmuOVA5QCEQvF2=	NXG5WVFqW0GQR1XS
A101D	NIHaUW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlfKTWM2OD12OT65O\|M3KM7:TR?=	NXeyXnM1W0GQR1XS

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pALK / pAKT / pERK / pS6; PubMed: 24675041 Cancer Discov H3122 cells were treated with the indicated concentrations of crizotinib or ceritinib for 6 hours. Lysates were probed with antibodies directed against the specified proteins. pROS1 / ROS1; PubMed: 25351743 Clin Cancer Res Inhibition of phospho-ROS1 by various ALK inhibitors in Ba/F3 models. CD74-ROS1 expressing Ba/F3 cells were exposed to increasing concentrations of crizotinib, ceritinib, AP26113, or ASP3026 for 3 h. Cell lysates were immunoblotted to detect the indicated proteins. pSTAT3 / STAT3; PubMed: 25351743 Clin Cancer Res Inhibition of phospho-ROS1 by various ALK inhibitors in Ba/F3 models. CD74-ROS1 expressing Ba/F3 cells were exposed to increasing concentrations of crizotinib, ceritinib, AP26113, or ASP3026 for 3 h. Cell lysates were immunoblotted to detect the indicated proteins. PARP / cleaved caspase-3 / Bax / Bcl-2; PubMed: 25193856 Oncotarget The expression of PARP, cleaved caspase-3, Bax, and Bcl-2 were measured by western blotting after PANC-1 cells were treated with various concentrations of Crizotinib (0-10 μM) for 72 hr. p-c-Met / c-Met; PubMed: 25193856 Oncotarget Cancer cells with c-MET alterations were exposed to Crizotinib (10 μM) in the indicated times (SNU-5, MKN-45, and SNU-638: gastric cancer cells of c-MET amplification). p-mTOR; PubMed: 26384345 Oncotarget Immunoblotting for phospho- or total MET, STAT3, AKT, MTOR and ERK in SPC-A1 cells treated with crizotinib for 48 h.	24675041 25351743 25193856 26384345
Immunofluorescence	LC3 / lysosome; PubMed: 26384345 Oncotarget Cells were treated with DMSO or 4 μM crizotinib for 72 h before they were labeled with a fluorescent marker and imaged by fluorescence microscopy. Green: FITC-labeled LC3; Red: lyso-tracker-labeled lysosome; Blue: DAPI-labeled nucleus. SRC / Met; PubMed: 26517812 Oncotarget Cellular localization of SRC and Met following treatment for 48 h with dasatinib, crizotinib or combination in (A) LN-18 and (B) U373 cells. Scale bar denotes 10 μm. Nuclei were visualized by DAPI while SRC and Met were labeled with a fluorescein and Texas-red conjugated secondary antibodies, respectively. α-tubulin; PubMed: 26517812 Oncotarget LN-18 cells were treated with dasatinib 0.2 μM, crizotinib 4 μM or their combination for 48 h. Mitotic spindle were visualized using α-tubulin antibody conjugated to a fluorescein-labeled secondary antibody. Nuclei were stained by DAPI. The scale bar denotes 10 μm. cytochrome c; PubMed: 25193856 Oncotarget PANC-1 pancreatic cancer cells were treated with Crizotinib (1 and 10 μM) for 6 hr and stained with anti-cytochrome c antibody, Mitotracker and DAPI. The immunostained cells were analyzed under an Olympus confocal laser scanning microscope with 400x magnification. Cytochrome c (green), mitotracker: red p-ALK; PubMed: 25193856 Oncotarget PANC-1 cells were also treated with various concentrations (0-10 μM) of Crizotinib and stained with p-ALK antibody and DAPI. The immunostained cells were analyzed under an Olympus confocal laser scanning microscope with 400x magnification.	26384345 26517812 25193856

体内研究

PF-2341066每天按50 mg/kg和75 mg/kg剂量处理GTL-16 模型, 引起大肿瘤 (体积大于600 mm³) 明显衰退，且按43天处理日程处理后，平均肿瘤体积降低60%。在另一项研究中, PF-2341066处理3个月以上，完全抑制GTL-16肿瘤生长，PF-2341066每天按50 mg/kg剂量处理小鼠，3个月后，只有1/12小鼠的肿瘤生长得到提高。PF-2341066每天按50 mg/kg剂量处理NCI-H441 NSCLC 模型处理周期为38天，观察到平均肿瘤体积降低43%。PF-2341066 每天按50 mg/kg剂量作用于 Caki-1 RCC模型，处理周期为33天，观察到平均肿瘤体积降低53%，且每种肿瘤体积降低至少30%。PF-2341066每天按 50 mg/kg剂量作用于 U87MG 恶性胶质瘤或PC-3前列腺癌移植瘤模型,几乎完全抑制肿瘤生长，在实验最后一天，抑制分别达97% 或84%。相反, PF-2341066每天按50 mg/kg剂量口服给药处理 MDA-MB-231 乳腺癌模型,或 DLD-1 结肠癌模型，不会显著抑制肿瘤生长。PF-2341066每天按12.5 mg/kg, 25 mg/kg, 和50 mg/kg剂量作用于 GTL-16 肿瘤，观察到CD31阳性内皮细胞显著降低，这种作用存在剂量依赖性，说明 MVD 受抑制，且具有相关的抗癌高效性，这种作用也存在剂量依赖性。PF-2341066 作用于GTL-16 和 U87MG 模型，显著降低人VEGFA 和IL-8血浆水平，这种作用存在剂量依赖性。PF-2341066口服处理GTL-16 肿瘤，观察到磷酸化的c-Met, Akt, Erk, PLCλ1,和 STAT5水平显著受抑制。^[1]PF-2341066 每天按100 mg/kg剂量口服处理携带Karpas299 ALCL 移植瘤的SCID Beige 小鼠，具有抗癌高效性，这种作用存在剂量依赖性，处理15天，所有肿瘤完全衰退。此外, PF-2341066抑制关键NPM-ALK信号调节器, 包括磷脂酶C-γ, 信号转导器，及转录因子3, 细胞外信号调节激酶, 和Akt的激活剂，这些与 NPM-ALK 磷酸化和功能受抑制相关。^[2] PF-2341066 抑制骨肉瘤的一些活动行为，及其肿瘤生长(例如, 增殖和存活)和转移 (例如，入侵和形成克隆)。PF-2341066口服饲喂裸鼠，抑制生长和相关的骨肉瘤裸鼠移植瘤的骨基质的形成。^[3] PF-2341066 按50 mg/kg 剂量处理 c-MET-扩增的GTL-16移植瘤，引起肿瘤衰退，这与¹⁸F-FDG 摄取的缓慢降低相关，且降低葡糖糖转运蛋白 1, GLUT-1的表达。^[4]

激酶实验： ^[1]	- 合并生化激酶实验: 使用连续耦合的分光光度测定c-Met催化活性，通过分析NADH消耗率而测定c-Met诱导的ADP产量，这种作用具有时间依赖性。在 340 nm处使用分光光度法在指定时间点测定吸光值的降低而计算NADH的消耗量。为了测定K_i值, 在含实验试剂的实验孔中加入不同浓度PF-2341066，然后在37^oC下温育10分钟。加入c-Met酶开始进行实验反应。
细胞实验： ^[1]	- 合并 Cell lines: GTL-16胃癌细胞和T47D乳腺癌细胞 Concentrations: 0 nM-256 nM Incubation Time: 1小时 Method: GTL-16胃癌细胞和T47D乳腺癌细胞接种在96孔板上，孔中含培养基，培养基中含10% 胎牛血清(FBS)，然后转移到无血清培养基中[含0.04%牛血清蛋白(BSA)]，处理 24小时。在调查配体依赖的RTK 磷酸化实验中，加入相应的生长因子，处理20分钟。细胞和 PF-2341066和/或适当配体在指定时间温育1小时，然后使用含 1 mmol/L Na₃VO₄的HBSS冲洗细胞一次,然后从细胞中获得蛋白裂解物。随后,通过夹心酶联免疫吸附试验法使用特定的捕获抗体在96孔板上测定选定蛋白激酶的磷酸化，使用特点检测抗体测定磷酸化的酪氨酸残基。抗体包被的实验板(a) 在蛋白裂解物存在时，在4^oC下过夜;(b)在溶于PBS的1% Tween-20 中冲洗7次;(c)在辣根过氧化物酶标记的抗总磷酸（PY-20）抗体（1:500）中温育20分钟;(d) 再次冲洗7次;(e)在3,3^′,5,5^′-四甲基联苯胺过氧化物酶底物中温育，开始显示反应，加入0.09 N H₂SO₄终止反应; (f)在450 nm 处使用分光光度计测定吸光度。 (Only for Reference)
动物实验： ^[1]	- 合并 Animal Models: 携带NCI-H441,或DLD-1,或MDA-MB-231的雌性和雄性nu/nu小鼠 Dosages: 12.5 mg/kg/day, 25 mg/kg/day, 和50 mg/kg/day Administration: 口服处理 (Only for Reference)

参考文献

- 合并

溶解度 (25°C)

体外	DMSO	9 mg/mL (19.98 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5% DMSO+30% PEG 300+dd H2O	5mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Crizotinib (PF-02341066) SDF

分子量	450.34
化学式	C₂₁H₂₂Cl₂FN₅O
CAS号	877399-52-5
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2020-05-15)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04148066	Recruiting	Diagnostic Test: ctDNA blood sample	Carcinoma Non-Small-Cell Lung	The Netherlands Cancer Institute\|Roche Pharma AG	July 17 2019	Phase 2
NCT03439215	Recruiting	Drug: Lorlatinib	Carcinoma Non-Small-Cell Lung	Fondazione Ricerca Traslazionale\|Clinical Research Technology S.r.l.	June 13 2017	Phase 2
NCT02946216	Unknown status	Genetic: ctDNA analysis	Non-small Cell Lung Cancer Stage III\|Non-Small-Cell Lung Cancer Metastatic\|Adenocarcinoma of Lung\|EGFR Wildtype	First People''s Hospital of Hangzhou	November 2016	--
NCT02511184	Terminated	Drug: Crizotinib\|Drug: Pembrolizumab	ALK-positive Advanced NSCLC	Pfizer\|Merck Sharp & Dohme Corp.	October 2015	Phase 1
NCT02419287	Unknown status	Drug: crizotinib	Anaplastic Large Cell Lymphoma ALK-Positive	University of Milano Bicocca	April 2015	Phase 2
NCT02499614	Unknown status	Drug: Crizotinib	Carcinoma Non-Small-Cell Lung	Fondazione Ricerca Traslazionale	December 2014	Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
Could you tell me whether this product represents the pure R-form of crizotinib, or is the the racemic Crizotinib, so a mixture of the S- and the R-form?
回答：
Our S1068 Crizotinib is R enantiomer(except batch 05 and 06, they are racemate), and S7505 is S enantiomer.

c-Met Signaling Pathway Map

c-Met Inhibitors with Unique Features

选择性强的c-Met抑制剂

PF-04217903 : C-Met-selective, IC50=4.8 nM.
活性最高的c-Met抑制剂

INCB28060 : C-Met, IC50=0.13 nM.
用于临床的c-Met抑制剂

Tivantinib (ARQ 197) : Phase III for Hepatocellular Carcinoma.
最新的c-Met抑制剂

EMD 1214063 ^New : Potent and selective c-Met inhibitor with IC50 of 4 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer.

研究领域

产品类型

Crizotinib (PF-02341066)

客户使用Selleck生产的Crizotinib (PF-02341066)发表文献255篇：

产品安全说明书

c-Met抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Crizotinib (PF-02341066) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2020-05-15)

技术支持

常见问题及建议解决方法

c-Met Signaling Pathway Map

c-Met Inhibitors with Unique Features

相关c-Met产品